Category: 58142-46-4

On November 5, 2015, Wu, Lingyun; Yao, Yuanshan; Chen, Zhaoguo; Chen, Shuhui published a patent.SDS of cas: 58142-46-4 The title of the patent was Preparation of isoquinolinesulfonyl derivatives as Rho kinase inhibitors. And the patent contained the following:

The invention relates to isoquinolinesulfonyl derivatives (e.g., I) and their pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical preparations comprising them, and their use as Rho kinase inhibitors. For instance, the invention compound I was prepared and gave a ROCK kinase inhibition IC50 value of <0.1μM. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).SDS of cas: 58142-46-4

The Article related to isoquinolinesulfonyl preparation rho kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.SDS of cas: 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On December 16, 2004, Yamada, Rintaro; Seto, Minoru published a patent.HPLC of Formula: 58142-46-4 The title of the patent was Preparation of diazaphenalene compounds as myosin-control light chains phosphorylation inhibitors. And the patent contained the following:

Title compounds I [R1 = H, chloro, OH; X1···X2 represents CH(R2)-CH(R3), etc.; R2, R3 = H, alkyl; A1, A11, A2, A21 = H, alkyl; Y = CH(A3), etc.; A3 = H, alkyl; Z = OH, etc.] were prepared For example, cyclization of compound II using potassium tert-butoxide followed by deprotection of tert-butoxycarbonyl group with HCl afforded compound III hydrochloride. In myosin regulatory light chains phosphorylation inhibition assays, the IC50 value of compound III·HCl was ≤10 μM. Compounds I are claimed to be useful for the treatment of glaucoma, bronchial asthma, etc. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).HPLC of Formula: 58142-46-4

The Article related to diazaphenalene preparation myosin regulatory light chain phosphorylation inhibitor, antiglaucoma diazaphenalene preparation myosin regulatory light chain phosphorylation inhibition, antiasthmatic diazaphenalene preparation myosin regulatory light chain phosphorylation inhibition and other aspects.HPLC of Formula: 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

Ray Choudhury, Abhijnan; Mukherjee, Santanu published an article in 2016, the title of the article was Enantioselective dearomatization of isoquinolines by anion-binding catalysis en route to cyclic α-aminophosphonates.Name: 4-Bromo-5-nitroisoquinoline And the article contains the following content:

An enantioselective dearomatization of isoquinolines has been developed using chiral anion-binding catalysis. This transformation, catalyzed by a simple and easy to prepare tert-leucine-based thiourea derivative, makes use of silyl phosphite as a nucleophile and generates cyclic α-aminophosphonates. This is the first time asym. anion-binding catalysis has been applied to the synthesis of α-aminophosphonates. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Name: 4-Bromo-5-nitroisoquinoline

The Article related to enantioselective dearomatization isoquinoline anion binding catalysis, cyclic alpha aminophosphonate preparation crystal mol structure, tert leucine based thiourea catalyzed silyl phosphite reaction isoquinoline and other aspects.Name: 4-Bromo-5-nitroisoquinoline

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On January 6, 1976, Serban, Alexander published a patent.Category: isoquinoline The title of the patent was 3-Chloro-5-acetamidoisoquinoline as a herbicide. And the patent contained the following:

Isoquinolines I (R = H, halo, NO2, NH2, AcNH, CN; R1 = H, Me, Bu, NO2, NH2, halo, CN, Me) and I.HR2 [R2 = Cl, CF3CO2, Br, iodide, C6Cl5O, 2,4-(O2N)2C6H3O, substituted phenoxy, ClCF2CO2, 2,4-(O2N)2C6H3CO2] (∼110 compounds), which possessed herbicidal, insecticidal, acaricidal, and fungicidal activity, were prepared Isoquinolines were nitrated by H2SO4-KNO3 to give nitro derivatives of I which were reduced to the amino derivatives; Sandmeyer or Schiemann reaction of aminoisoquinolines yielded halo derivatives of I. The title compound was a selective herbicide at 0.25-10 lb/acre against ipomoea, mustard, and sunflower in areas cultivated in wheat, peas, yegrass, or oats. I.HR2 (R = H, 5-Cl, 5-Br, 5-NO2; R1 = H, 1-Me; R2 = Cl, substituted phenoxy) controlled cabbage moth at 0.2% weight/vol and I.HR2 (R = H, 5-NO2; R1 = H, 3-Me; R2 = iodide, CF3CO2) at 1% weight/volume possessed ∼100% effective acaricidal activity against cattle tick nymphs and engorged adults. 4-Bromo-5-nitroisoquinoline possessed fungicidal activity against wheat powdery mildew at 0.008% weight/volume The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Category: isoquinoline

The Article related to isoquinoline nitro insecticide, haloisoquinoline herbicide, nitroalkylisoquinoline acaricide, bromonitroisoquinoline fungicide, chloroacetamidoisoquinoline herbicide, acetamidochloroisoquinoline herbicide and other aspects.Category: isoquinoline

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On July 25, 2002, Nichols, David Earl; Mailman, Richard Bernard; Huang, Xuemei published a patent.SDS of cas: 58142-46-4 The title of the patent was Method using D1 dopamine receptor agonists for treatment of dopamine-related dysfunction. And the patent contained the following:

The invention relates to the treatment of dopamine-related dysfunction using full D1 dopamine receptor agonists in an intermittent dosing protocol with a short, but essential, “”off-period””. The D1 agonist concentration is reduced during the “”off-period”” to obtain a plasma concentration of agonist that suboptimally activates D1 dopamine receptors for a period of time to prevent induction of tolerance. Specifically, the method comprises administering to a patient a full D1 agonist with a half-life of up to about 6 h periodically at a dose resulting in a first plasma concentration of agonist capable of activating D1 dopamine receptors to produce a therapeutic effect. The dose is reduced at least once every 24 h to obtain a second lower plasma concentration of agonist which results in suboptimal activation of D1 dopamine receptors for a period of time sufficient to prevent induction of tolerance. The dopamine D1 agonist is e.g. dinoxyline (preparation described). The methodol. of the invention may be used to treat e.g. Parkinson’s disease. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).SDS of cas: 58142-46-4

The Article related to dopamine related disease treatment d1 agonist tolerance prevention, dinoxyline preparation d1 agonist dopamine disease treatment, parkinson disease dopamine d1 agonist tolerance prevention and other aspects.SDS of cas: 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On February 2, 2006, Fernandes, Prabhavathi B.; Mailman, Richard Bernard; Nichols, David Earl published a patent.Recommanded Product: 4-Bromo-5-nitroisoquinoline The title of the patent was Preparation of hexahydrobenzophenanthridines as dopamine receptor agonists for treatment of pulmonary edema. And the patent contained the following:

The title hexahydrobenzophenanthridines, hexahydrothienophenanthridines, phenylbenzodiazepines, chromenoisoquinolines, and naphthoisoquinolines with general formula of I and II [wherein X = H, OH, alkoxy, etc.; Y = O or (un)substituted CH2; R = H or alkyl; R1 = H, alkyl, acyl, etc.; R2-R4 = independently H, alkyl, Ph, halo, etc; R5-R7 = independently H, alkyl, or alkenyl; R8-R10 = independently H, OH, alkyl, Ph, halo, or alkoxy; R11 = H, alkyl, acyl, etc.; R12 = H, OH, alkoxy, etc.], or pharmaceutically acceptable salts thereof were prepared as dopamine receptor agonists for the treatment of pulmonary edema. For example, III was prepared in a multi-step synthesis. III showed agonistic activity with EC50 of 28±9 and 10±2 nM against human D1-like and D5 receptors, resp. Formulations as aerosols and dry powders, and methods for treating a patient having pulmonary edema are described. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Recommanded Product: 4-Bromo-5-nitroisoquinoline

The Article related to dopamine receptor agonist treatment pulmonary edema formulation human, preparation benzophenanthridine thienophenanthridine phenylbenzodiazepine chromenoisoquinoline naphthoisoquinoline and other aspects.Recommanded Product: 4-Bromo-5-nitroisoquinoline

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On September 25, 1975, Serban, Alexander published a patent.HPLC of Formula: 58142-46-4 The title of the patent was Isoquinolines. And the patent contained the following:

Substituted isoquinolines (I, where R1, R3, R4, R5, R6, R7 and R8 = H, alkyl, halo, nitro, amino, mono- and dialkyl substituted amino, mono- and diaryl substituted amino, acyl substituted amino, cyano, arylthio, alkylthio, and salts of these compounds) were prepared and are effective in controlling or eradicating undesired vegetation, insects, acarina, or fungi. Thus, 4-bromo-5-nitroisoquinoline (I) [58142-46-4], prepared by nitration of 4-bromoisoquinoline [1532-97-4], showed fungicidal activity. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).HPLC of Formula: 58142-46-4

The Article related to fungicide isoquinoline derivative, herbicide isoquinoline derivative, acaricide isoquinoline derivative, insecticide isoquinoline derivative, isoquinoline derivative pesticide and other aspects.HPLC of Formula: 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On June 1, 2006, Yamada, Rintaro; Seto, Minoru published a patent.Application In Synthesis of 4-Bromo-5-nitroisoquinoline The title of the patent was Preparation of diazaphenalene derivatives as myosin-control light chains phosphorylation inhibitors. And the patent contained the following:

Title compounds I [R1, R5-R8 = H, halo, hydroxy, etc.; X1···X2 = -CH(R2)CH(R3)-, -CH(R2)CH(R3)CH(R4)-, -C(R2):C(R3)-, etc.; R2-R4 = H, alkyl; A1, A11, A2, A21 = H, alkyl; Y = -CH(A3)-, -CH(A3)C(A4)(A41)-, single bond, etc.; A3, A4, A41 = H, alkyl; Z = hydroxy, -NR(A6)(A61); A6 = H, alkyl; A61 = H, alkyl, alkyl substituted with aryl group, etc.; further details on A1-A4 and A6 are given.] and salts thereof were prepared For example, reductive amination of tert-Bu 3-oxo-1-piperidinecarboxylate with 5-amino-4-vinylisoquinoline, e.g., prepared from 5-amino-4-bromoisoquinoline, followed by reaction with potassium tert-butoxide and treatment with HCl afforded compound II hydrochloride. In myosin-control light chains phosphorylation inhibition assays, compound II hydrochloride exhibited the IC50 value of ≤10 μM. Compounds I are claimed useful for the treatment of glaucoma, bronchial asthma, etc. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Application In Synthesis of 4-Bromo-5-nitroisoquinoline

The Article related to diazaphenalene preparation myosin control light chain phosphorylation inhibitor, glaucoma bronchial asthma treatment diazaphenalene preparation, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Application In Synthesis of 4-Bromo-5-nitroisoquinoline

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On December 28, 2000, Nichols, David E.; Grubbs, Russell A.; Mailman, Richard B. published a patent.Electric Literature of 58142-46-4 The title of the patent was Preparation of chromeno[4,3,2-de]isoquinolines as potent dopamine receptor ligands. And the patent contained the following:

The title compounds I [R1, R2, R3 = H, alkyl, alkenyl; R8 = H, alkyl, phenoxy protecting group; X9 = H, halo, OR where R = H, alkyl, phenoxy protecting group, etc.; R4, R5, R6 = H, alkyl, Ph, halo, OR], potent dopamine receptor ligands, were prepared E.g., N-propyl-8,9-dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2-de]isoquinoline was prepared The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Electric Literature of 58142-46-4

The Article related to chromenoisoquinoline preparation dopamine receptor ligand, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Electric Literature of 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On November 25, 2015, Wu, Lingyun; Yao, Yuanshan; Chen, Zhaoguo; Chen, Shuhui published a patent.Quality Control of 4-Bromo-5-nitroisoquinoline The title of the patent was Preparation of isoquinolinesulfonyl derivatives as Rho kinase inhibitors. And the patent contained the following:

The invention relates to isoquinolinesulfonyl derivatives (e.g., I) and their pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical preparations comprising them, and their use as Rho kinase inhibitors. For instance, the invention compound I was prepared and gave a ROCK kinase inhibition IC50 value of <0.1μM. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Quality Control of 4-Bromo-5-nitroisoquinoline

The Article related to isoquinolinesulfonyl preparation rho kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Quality Control of 4-Bromo-5-nitroisoquinoline

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem